relative to clonidine and decreases its corneal penetration coefficient and ability to cross the blood-brain barrier. � Apraclonidine has fewer centrally mediated cardiovascular side effects than clonidine h" However, allergic reactions occur in 19-36% of patients using apraclonidine documented in all subjects with slit lamp photography.
Conjunctival follicles, papillae, erythema and oedema were graded on a scale of 0 (absent) to 3 (severe) by one observer. Apraclonidine was then discontinued until the allergy resolved. Grading and photography were repeated, following which brimonidine treatment was initiated. Patients were examined 1 h after instillation of the initial drop of brimonidine, and then twice weekly for 6 weeks, at 3 months, and then at 3 monthly intervals. At each visit, patients were questioned about symptoms of ocular redness, discomfort and itching, and were instructed to return for examination immediately if these symptoms of allergy developed between study visits. Photography was repeated at the 6 month visit or when an allergic response occurred.
All subjects used apraclonidine or brimonidine in conjunction with other anti-glaucoma medications. The number and dosage of these other anti-glaucoma medications were not altered during the study period.
Results
Mean patient age was 66.3 :!:: 14.9 years (range 33.5-89.3 years). For 4 patients with a history of apraclonidine allergy, medical records were not available to determine the time from initial exposure to the development of the allergic response. For the remaining 14, the mean time to diagnosis of allergy from initial exposure was 12.9 :!:: 12.9 months (range 2.1-46.8 months). For the 10 patients rechallenged with apraclonidine, the mean time to allergy was 13.6 :!:: 10.2 days (range 3-32 days). For the 8 patients newly presenting with apraclonidine allergy, the signs of allergic response remitted in all cases after washout and prior to institution of brimonidine therapy, indicating apraclonidine to have been responsible for the allergic response. The mean time for apraclonidine washout and allergy resolution was 19.9 :!:: 11.7 days (range 8-56 days).
Mean duration of brimonidine therapy was 140.7 :!:: 66.2 days (range 14-286 days), with 11 patients reaching at least 150 days of follow-up. Two patients developed symptomatic brimonidine aJlergy at 138 and 201 days respectively. They reported no difference in the degree of itching and redness between apraclonidine and brimonidine allergies. In both these patients, signs of allergy remitted soon after discontinuation of brimonidine. Five patients discontinued brimonidine therapy for reasons other than allergy (1 patient moved away and 4 others underwent trabeculectomy). A summary of apraclonidine rechallenge and duration of brimonidine therapy is provided in Table 1 .
The change in allergy grading parameters at each study interval is outlined in Table 2 . From apraclonidine allergy to washout there was a decrease in conjunctival follicles (p<O.OO1, chi-squared), papillae (p = 0.002), All parameters improved from the time of apraclonidine allergy to washout, while there were no significant differences in any parameter throughout the 6 months of brimonidine therapy.
erythema ( p = 0.003) and oedema ( p = 0.070). There was no significant change in any of these parameters from the completion of the washout period to study endpoint.
Comment
The mean time from initial apraclonidine exposure to diagnosis of allergy in this study was 12. 
